Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $66.26, for a total transaction of $144,446.80. Following the transaction, the director directly owned 1,107,504 shares in the company, valued at $73,383,215.04. This represents a 0.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Quiros Juan Jose Chacon also recently made the following trade(s):
- On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total transaction of $1,985,108.84.
- On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The shares were sold at an average price of $65.43, for a total transaction of $2,790,066.06.
- On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The shares were sold at an average price of $65.23, for a total transaction of $2,446,125.00.
- On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The shares were sold at an average price of $60.08, for a total transaction of $214,786.00.
- On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75.
Establishment Labs Price Performance
Shares of NASDAQ:ESTA opened at $65.47 on Tuesday. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a 1-year low of $28.89 and a 1-year high of $83.31. The company has a market capitalization of $1.92 billion, a P/E ratio of -37.63 and a beta of 1.08. The firm's 50 day simple moving average is $66.15 and its two-hundred day simple moving average is $65.53.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. During the same quarter in the previous year, the firm earned ($1.19) earnings per share. The company's revenue for the quarter was up 45.2% on a year-over-year basis. Research analysts expect that Establishment Labs Holdings Inc. will post -0.86 EPS for the current fiscal year.
Hedge Funds Weigh In On Establishment Labs
Hedge funds have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of Establishment Labs in the third quarter worth $34,000. Kestra Advisory Services LLC purchased a new position in shares of Establishment Labs in the fourth quarter worth $47,000. State of Wyoming purchased a new position in shares of Establishment Labs in the third quarter worth $71,000. Osaic Holdings Inc. lifted its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after buying an additional 1,800 shares in the last quarter. Finally, MV Capital Management Inc. bought a new stake in Establishment Labs in the fourth quarter worth $146,000. Hedge funds and other institutional investors own 72.91% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the stock. BTIG Research lifted their price target on shares of Establishment Labs from $86.00 to $88.00 and gave the company a "buy" rating in a report on Tuesday, February 24th. Needham & Company LLC boosted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th. Stephens boosted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Mizuho boosted their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Establishment Labs from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $86.86.
Check Out Our Latest Stock Analysis on ESTA
Establishment Labs Company Profile
(
Get Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
